The Future of Biotech Outsourcing

Features

Cell & Gene Therapy CDMO Partnerships

Alliances and expertise behind advancing CGTs in today’s market.

SPONSOR

DNA-to-IND in as little as 6 months

Our enhanced offering enables mAb programs to achieve IND readiness in as little as 6 months, with tox?grade DS available in ~2 months.

Features

Building Cell Therapy the Right Way

Realize safe, scalable, and compliant cell therapies by building analytical strategies that exceed regulatory expectations.

Online Exclusives

Inside Biomanufacturing’s Quality Overhaul as Complex Drugs Surge

How today’s manufacturers are filling the growing need for biologics without rushing complex processes in development or quality control.

SPONSOR

Avoid the Hidden Costs of Late-Stage Reformulation

Addressing manufacturability late causes scale-up & stability issues. Serán builds scalable oral drug formulations from the start.

Expert’s Opinion

Biotech’s Great Reset: Smart Capital and Smarter Manufacturing Converge

The intersection where science meets production is where real value is created.

SPONSOR

Master quality and compliance in SI fill-finish

Pfizer experts explore how to navigate rising regulatory demands while keeping complex sterile injectables on track. Download the eBook.

SPONSOR

Taking off with the right CDMO

Biopharma companies face a complex journey as they strive to transform groundbreaking ideas into life-saving therapeutics. The process is fraught with challenges, also driven by current geopolitical changes. This playbook explores how CDMOs can help.

Solution Center SPOTLIGHT

MG America

MG America is a recognized leader in supplying today’s finest European-crafted packaging and processing machinery to leading pharmaceutical, nutritional, OTC and medical device companies located throughout the United States, Canada and Puerto Rico. The company takes tremendous pride in the relationships that it builds with its customers.

Solution Center SPOTLIGHT

ESTEVE CDMO

We are a leading provider of high-quality small-molecule APIs and pharmaceutical intermediates. With over 55 years of expertise and a proven track record in developing numerous new chemical entity (NCE) products across diverse therapeutic areas, we have established ourselves as a trusted partner for innovative pharmaceutical companies worldwide.